Hepatitis A booster vaccination: is there a need?

Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted

“…The World Health Organization calls for two vaccine doses administered 6 to 18 months apart when childhood immunization is recommended (51). Citing long-term antibody persistence and evidence that immune memory persists after loss of detectable antibody, an expert panel concludes there is no evidence to support booster vaccination in healthy individuals after a two-dose series (52). The same panel calls for studies exploring long-term protection after a single dose, concluding it is currently not established (52).…”

“…Citing long-term antibody persistence and evidence that immune memory persists after loss of detectable antibody, an expert panel concludes there is no evidence to support booster vaccination in healthy individuals after a two-dose series (52). The same panel calls for studies exploring long-term protection after a single dose, concluding it is currently not established (52). Our reference case assumptions regarding duration of protection are based on another expert panel's opinion (42).…”

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial

“…5,6 Predictive modeling has been applied to estimate the persistence of antibodies induced following hepatitis A and B vaccination. [7][8][9] The aims of the end-of-study analysis reported here are: 1) to evaluate the serum antibody response of the HPV-16/18 and the HPV-6/11/16/18 vaccines measured by pseudovirion-based neutralization assay (PBNA) and enzyme-linked immunosorbent assay (ELISA) through Month 60 (i.e., 54 months after completion of the full vaccination series); 2) to predict the long-term persistence of vaccine-induced anti-HPV-16 and anti-HPV-18 antibody responses (PBNA, ELISA) in subjects receiving a full series of vaccination by applying statistical models to antibody levels measured during the 5-y study duration; and 3) to evaluate safety up to Month 60. Month 60 ATP cohort for immunogenicity included all evaluable subjects who received 3 vaccine doses (i.e., those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning immunogenicity endpoint measures were available.…”

Marked decrease in the incidence and prevalence of hepatitis A in the Basque Country, Spain, 1986–2004

“…Hepatitis A causes considerable economic losses in many countries of middle or low endemicity, in which the infection frequently affects adults [1,2]. Several highly effective vaccines against hepatitis A virus (HAV) are available, which generate long-term, and possibly lifelong, immunity [1,4]. Recommendations on vaccination vary from country to country, oscillating from selective vaccination of at-risk groups to universal vaccination [1].…”